Timing Is Everything
"After all, in life, timing is everything." So concludes a review article 1 on the use of principles of chronobiology to modulate delivery of cancer chemotherapy agents in this issue of Integrative Cancer Therapies (ICT). The article is authored by Christopher Lis, William Hrushesky, and others. Dr Hrushesky has been the major contributor to studies of chronobiology in cancer for many years and is an active member of the Advisory Board at ICT. Chronomodulated chemotherapy (often called "chronotherapy") builds on the observation that the cytotoxicity of many chemotherapy agents varies according to circadian timing of administration of the drugs. This effect arises because of the circadian timing of a multitude of biological functions, including entry of cancerous and healthy cells into different stages of the cell cycle. Because of the synchronized and time-delimited passage of cancer cells through the cell cycle on a daily basis, it has been possible to map out times of day when different tumors have the highest susceptibility to cytotoxic agents and when susceptibility to toxicity is lowest, and to use this knowledge in developing innovative drug delivery protocols for a variety of cancers. Because chronotherapy is based on a principle of working in concert with natural biological processes to improve outcomes and quality of life, and thereby blends conventional medicine with natural approaches to and understandings of health, I consider chronotherapy a clinically important modality in integrative cancer care.
Knowing when this peak of susceptibility to cytotoxic drugs occurs has enabled investigators, mostly in Europe, to develop protocols in which chemotherapy drugs are infused continuously, but with a peak rate of infusion at the time of day or night in which cells of a particular cancer type are most sensitive to cytotoxic agents. Administration of chemotherapeutic drugs with variable peak infusion rates is facilitated by the use of special programmable pumps. As discussed in this issue's review article, multiple randomized trials indicate both an increase in efficacy and a reduction in adverse side effects of chemotherapeutic agents when cancers are treated with chronomodulated chemotherapy. In an era of evidence-based medicine, it appears that the time may have come for the physicians in the United States to take seriously the findings of these trials and begin to implement a system that improves both outcomes and quality of life for our patients.
In medical life, though, timing is not necessarily everything. Reimbursement, arguably, is. And in the United States, it is apparent that reimbursement for chronotherapy is not yet a given. Because I have successfully used chronotherapy in my medical practice in Evanston, Illinois, for many years, 2 I have developed a particular interest in it. I recently published the results of a survey of reimbursement patterns for chronotherapy in the United States. 3 My staff and I contacted 4 health maintenance organizations, 4 preferred provider organizations, 4 indemnity plan companies, and Medicare and Medicaid to inquire (a) whether they were familiar with research on chronotherapy, (b) whether they were aware of the reduced side effects and increased efficacy shown in studies of chronotherapy, (c) whether they recognized chronotherapy protocols as a standard of care for cancer patients, and (d) whether they reimbursed for chronotherapy treatments. The answer to all of these questions by all providers was a resounding no, except for one PPO, which was aware of the research and its results, but still did not reimburse for chronotherapy treatments.
It is curious that chronotherapy protocols that are supported by numerous and large randomized trials, built on a solid biological foundation, and improve outcomes and quality of life still receive so little support in the United States, even though they are widely used in countries across Europe. Certainly one reason for this is a simple lack of familiarity with the ways that chronotherapy protocols can be implemented in the average medical practice. Our Integrative Tumor Board in this issue attempts to address this question. It concerns a patient who has colon cancer with liver metastases, one of the conditions for which chronotherapy has particularly good evidence. The usefulness of chronomodulated chemotherapy in this setting and its practicality are discussed by 2 members of our staff at the Block Center for Integrative Cancer Care. A very different perspective involving timing of integrative treatments through the use of traditional Chinese medicine is offered by members of the Pine Street Clinic in San Francisco. Other contributions to the Tumor Board discuss the approaches of Wellness House, a Chicago-area cancer support center, and the nutritional concerns to be considered with colon cancer patients. A thorough medical oncology analysis is presented by physicians from the University of Illinois at Chicago.
We are very pleased to feature in this issue the results of an analysis of one of the major alternative cancer approaches, immunoaugmentative therapy, by Bernd L. Pfeifer and Wayne B. Jonas, the former head of the National Center for Complementary and Alternative Medicine (then the Office of Alternative Medicine) at the U.S. National Institutes of Health. Dr Jonas is also a member of the Advisory Board at ICT. This study is based on the results of a system of evaluation of alternative cancer therapies called the Prospective Outcomes Documentation System (PODS). PODS is a prospective method that can be used to explore the potential contributions of alternative treatment methods in an objective and systematic fashion. The quality of the analysis presented in this article certainly confirms the usefulness of this method.
A retrospective study of another major alternative cancer treatment, orthomolecular medicine, appeared in December 2002. 4 This study forms the basis of our Point-Counterpoint in this issue. We have changed our typical Point-Counterpoint format for this topic, and rather than asking different authorities the same questions, have provided a forum for different authorities to address different questions related to the topic. Abram Hoffer, whose orthomolecular approach was the subject of the retrospective study, gives his reactions to it. Debu Tripathy, of the University of Texas Southwestern Medical Center, and another ICT Advisory Board member, contributes important considerations on the conduct of research on alternative cancer therapies, whereas David Golde, of Memorial Sloan-Kettering, presents his perspectives on vitamin C as an alternative treatment. We also feature an ICT staff article reviewing past studies of vitamin C in cancer therapy as background for the discussions of the other authors.
An article by Colleen Piersen of the Center for Dietary Supplements Research at the University of Illinois College of Pharmacy represents an extremely interesting and important contribution to the resolution of persistent questions about the role of phytoestrogens for breast cancer patients. She addresses in thorough scientific detail the estrogenic and nonestrogenic biological activities of the various herbal medicines used for menopausal difficulties such as hot flashes and night sweats. The possibility of estrogenic activities in these herbals, and the ways in which they might relate to breast cancer, is of special concern to patients with estrogen-receptor-positive breast cancers, and this detailed review will be significantly useful to practitioners counseling these patients.
As we have noted in previous editorials, cancer prevention is as much a subject of interest to Integrative Cancer Therapies as cancer treatment. In this issue, we feature an educational review concerning the use of detoxification agents as potential cancer preventives, with a focus on D-glucaric acid. The article, authored by Margaret Hanausek, Zbigniew Walaszek and Thomas J. Slaga of the AMC Cancer Center in Denver, is a thorough scientific exploration of detoxification mechanisms and a variety of natural compounds that work with them.
